Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 10(9): e0138539, 2015.
Article in English | MEDLINE | ID: mdl-26382957

ABSTRACT

Neointimal formation and cell proliferation resulting into in-stent restenosis is a major pathophysiological event following the deployment of stents in the coronary arteries. In this study, we assessed the degree of injury, based on damage to internal elastic lamina, media, external elastic lamina, and adventitia following the intravascular stenting, and its relationship with the degree of smooth muscle cell proliferation. We examined the smooth muscle cell proliferation and their phenotype at different levels of stent injury in the coronary arteries of domestic swine fed a normal swine diet. Five weeks after stent implantation, swine with and without stents were euthanized and coronaries were excised. Arteries were embedded in methyl methacrylate and sections were stained with H&E, trichrome, and Movat's pentachrome. The expression of Ki67, α-smooth muscle actin (SMA), vimentin, and HMGB1 was evaluated by immunofluorescence. There was a positive correlation between percent area stenosis and injury score. The distribution of SMA and vimentin was correlated with the degree of arterial injury such that arteries that had an injury score >2 did not have immunoreactivity to SMA in the neointimal cells near the stent struts, but these neointimal cells were positive for vimentin, suggesting a change in the smooth muscle cell phenotype. The Ki67 and HMGB1 immunoreactivity was highly correlated with the fragmentation of the IEL and injury in the tunica media. Thus, the extent of coronary arterial injury during interventional procedure will dictate the degree of neointimal hyperplasia, in-stent restenosis, and smooth muscle cell phenotype.


Subject(s)
Actins/metabolism , Cell Proliferation/physiology , Coronary Vessels/metabolism , Myocytes, Smooth Muscle/metabolism , Stents , Animals , Coronary Vessels/cytology , Coronary Vessels/surgery , HMGB1 Protein/metabolism , Myocytes, Smooth Muscle/cytology , Neointima/metabolism , Swine , Tunica Intima/metabolism
2.
Immunol Cell Biol ; 83(6): 651-67, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16266318

ABSTRACT

Insulin-like growth factor (IGF)-1 has been implicated in the development of occlusive vascular lesions. Although its role in vascular smooth muscle cell (VSMC) growth and migration are fairly well characterized, anti-apoptotic signals of IGF-1 in human VSMC remain largely unknown. In this study, we examined IGF-1 signals that protect human and rat VSMC from staurosporine (STAU)- and c-myc- induced apoptosis, respectively. Treatment with STAU resulted in apoptotic DNA fragmentation, phosphatidylserine externalization and cell shrinkage, but only occasional VSMC 'blebbing'. STAU-induced death and IGF-1-mediated survival were concentration dependent, while time-lapse video microscopy showed that IGF-1 inhibited c-myc-induced apoptosis by 90%. Pretreatment with mitogen-activated protein kinase/extracellular signal regulated kinase kinase (MEK) inhibitors UO126 and PD098059, or with the phosphatidylinositol 3-kinase (PI3-K) inhibitor wortmannin, reversed IGF-1-mediated human VSMC survival by 25-27% and 66%, respectively. Translocation studies showed that IGF-1 activated protein kinase C (PKC)-epsilon, but not PKC-alpha or PKC-delta, even in the presence of STAU, while pharmacological PKC inhibition (Ro-318220 or Go6976) implicated PKC-zeta or a novel PKC isozyme in IGF-1-mediated survival. Transient expression of activated PKC-epsilon but not activated PKC-zeta decreased myc-induced apoptosis in rat VSMC. In human VSMC, antisense oligodeoxynucleotides to PKC-epsilon partially reversed IGF-1-induced survival. In addition, IGF-1 elicited a mild but sustained activation of extracellular signal regulated kinase (ERK)1/2 in human VSMC that was abolished after 1 h in the presence of STAU. PKC downregulation reversed both IGF-1- and PMA-induced ERK activity, but platelet-derived growth factor (PDGF)-induced activity was unchanged. These results indicate for the first time that IGF-1 can protect human VSMC via multiple signals, including PKC-epsilon, PI3-K and mitogen-activated protein kinase pathways.


Subject(s)
Apoptosis/drug effects , Insulin-Like Growth Factor I/pharmacology , MAP Kinase Signaling System/drug effects , Muscle, Smooth, Vascular/drug effects , Phosphatidylinositol 3-Kinases/metabolism , Protein Kinase C-epsilon/metabolism , Cell Shape/drug effects , Cells, Cultured , Humans , Microscopy, Electron, Scanning , Mitogen-Activated Protein Kinase Kinases/metabolism , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/enzymology , Muscle, Smooth, Vascular/ultrastructure , Staurosporine/pharmacology
3.
Int Immunopharmacol ; 3(13-14): 1751-9, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14636826

ABSTRACT

Vascular smooth muscle cells (VSMCs) play a major role in the development of atherosclerotic and restenotic lesions. The apoptotic process has been implicated in the development of this pathology. In this study, we characterized the induction of apoptosis by calphostin C (CC), a protein kinase C (PKC) inhibitor, in primary human coronary artery smooth muscle cells in the presence and absence of insulin-like growth factor-I (IGF-I). Additionally, we investigated the signal transduction pathways important for IGF-I mediated protection. Calphostin C induced apoptosis, as measured by terminal deoxy-UTP nick-end labeling (TUNEL), in a time- and dose-dependent manner, approaching 20% within 6 h of 50 nM calphostin C treatment. The amount of apoptosis increased to 44.58+/-8.08%, 47.54+/-1.66% and 78.1+/-11.9% after 8, 10 and 12 h of treatment, respectively (p<0.01 vs. control). IGF-I offered significant protection (p<0.05) at 8 and 10 h of treatment (60.6% and 52.5% protection, respectively). DNA ELISA confirmed the apoptotic effect of calphostin C and the protective effect of IGF-I. After 6 h of calphostin C treatment, DNA ELISA revealed 11.20+/-1.53 fold greater apoptosis as compared to baseline values. IGF-I treatment offered a level of protection of 46.6% as measured by DNA ELISA (p=0.06). Apoptosis was further qualitatively confirmed by time-lapse video microscopy and scanning electron microscopy. Interestingly, inhibitors of phosphatidylinositol-3-kinase (PI-3-K), p38 and extracellular regulated kinase (ERK) activation significantly (p<0.05 vs. calphostin C only treatment) increased apoptosis when used in conjunction with calphostin C. Inhibitors of phospatidylinositol-3-kinase and ERK activation reversed IGF-I protection. However, the p38 inhibitor SB203580 failed to reverse IGF-I protection. This study characterized an apoptotic system for human coronary artery smooth muscle cells offering a rapid and strong induction of programmed cell death (PCD) that remains responsive to the survival effects of IGF-I. Studies utilizing this system may prove useful in understanding the apoptotic response of VSMCs in the arterial wall.


Subject(s)
Apoptosis/drug effects , Coronary Vessels/drug effects , Muscle, Smooth, Vascular/drug effects , Naphthalenes/adverse effects , Androstadienes/adverse effects , Animals , Cells, Cultured , Chromones/adverse effects , Coronary Vessels/pathology , Coronary Vessels/ultrastructure , Dose-Response Relationship, Drug , Drug Synergism , Drug Therapy, Combination , Enzyme-Linked Immunosorbent Assay , Flavonoids/adverse effects , Humans , Imidazoles/pharmacology , In Situ Nick-End Labeling/methods , Insulin-Like Growth Factor I/antagonists & inhibitors , Insulin-Like Growth Factor I/therapeutic use , Microscopy, Electron, Scanning/methods , Microscopy, Video/methods , Mitogen-Activated Protein Kinases/adverse effects , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Morpholines/adverse effects , Muscle, Smooth, Vascular/pathology , Muscle, Smooth, Vascular/ultrastructure , Naphthalenes/antagonists & inhibitors , Phosphatidylinositol 3-Kinases/adverse effects , Phosphoinositide-3 Kinase Inhibitors , Pyridines/pharmacology , Signal Transduction , Staurosporine/pharmacology , Time Factors , Wortmannin , p38 Mitogen-Activated Protein Kinases
SELECTION OF CITATIONS
SEARCH DETAIL
...